<document xmlns="http://cnx.rice.edu/cnxml">
  <title>Xanthines, Leukotriene Modifiers, Mast Cell Stabilizers, and Immunosuppressant Monoclonal Antibodies</title>
  <metadata xmlns:md="http://cnx.rice.edu/mdml">
    <md:title>Xanthines, Leukotriene Modifiers, Mast Cell Stabilizers, and Immunosuppressant Monoclonal Antibodies</md:title>
    <md:content-id>m00402</md:content-id>
    <md:uuid>8119dc74-635f-4e21-9c31-72ef25fd1e03</md:uuid>
  </metadata>
<content>
<section class="learning-objectives" id="sect-00001">
<title>Learning Outcomes</title>
<para id="para-00001">By the end of this section, you should be able to:</para>
<list id="list-00001">
<item>Identify the characteristics of xanthines, leukotriene modifiers, and mast cell stabilizers used to treat respiratory disorders.</item>
<item>Explain the indications, actions, adverse reactions, and interactions of xanthines, leukotriene modifiers, and mast cell stabilizers used to treat respiratory disorders.</item>
<item>Describe nursing implications of xanthines, leukotriene modifiers, and mast cell stabilizers used to treat respiratory disorders.</item>
<item>Explain the client education related to xanthines, leukotriene modifiers, and mast cell stabilizers used to treat respiratory disorders.</item>
</list>
</section>
<section id="sect-00002">
<title/>
<section id="sect-00003">
<title>Xanthines</title>
<para id="para-00002"><term id="term-00001">Xanthines</term> are a class of drugs that have been used for many years to manage respiratory conditions, particularly asthma and COPD. Xanthines work by relaxing the smooth muscles in the airways, which helps to open the bronchial passages and improve breathing. They also have some anti-inflammatory effects and can enhance the contractility of the diaphragm.</para>
<para id="para-00003">The primary xanthine medication used in clinical practice is theophylline. Aminophylline is another xanthine that can be used to treat asthma and COPD; however, it has a very narrow therapeutic index and even with regular monitoring can lead to adverse effects.</para>
<para id="para-00004">Theophylline is typically administered orally or intravenously (Khan, 2021). It has a narrow therapeutic window, requiring careful monitoring of blood levels to ensure efficacy and prevent toxicity. The therapeutic serum levels of theophylline are 10–20 mcg/mL. Doses should be adjusted so that levels are maintained at the lowest level within this range that produces a symptomatic response (DailyMed, <emphasis effect="italics">Theophylline</emphasis>, 2022). Clients with theophylline toxicity may present with abdominal pain, blurred vision, confusion, nausea, and vomiting. Although the use of xanthines has decreased with the advent of newer medications, they still play a role in certain situations and can be a valuable option for clients who do not respond well to other treatments. Clients taking theophylline should avoid other CNS stimulants such as caffeine (Cunha, 2021).</para>
<para id="para-00005"><link target-id="table-00001" document="m00402"/> lists common xanthines used for lower respiratory system disorders and typical routes and dosing for adult clients.</para>
<table class="vertically-tight" id="table-00001">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="2*"/>
<thead>
<row>
<entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Drug</span></emphasis></entry>
<entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Routes and Dosage Ranges</span></emphasis></entry>
</row>
</thead>
<tbody>
<row>
<entry valign="top" align="center"><term class="no-emphasis" id="term-00002">Theophylline</term><newline/>
(<term class="no-emphasis" id="term-00003">Theobid, Theo-24</term>)</entry>
<entry valign="top" align="center"><emphasis effect="bold">Parenteral theophylline (preferred route) for acute bronchospasm in clients not currently receiving theophylline:</emphasis><newline/>
Loading dose: 4.6 mg/kg of ideal body weight IV over 30 minutes, then maintenance infusion of 400–1600 mg/day<newline/>
<emphasis effect="italics">Adults over age 60:</emphasis> 0.3 mg/kg/hour IV, up to a maximum of 17 mg/hour.<newline/>
<emphasis effect="bold">Oral theophylline for acute bronchospasm in clients not currently receiving theophylline:</emphasis><newline/>
<emphasis effect="italics">Adults age 60 and younger:</emphasis> 5 mg/kg orally, then 300 mg (immediate-release solution/elixir) orally daily in divided doses every 6–8 hours for 3 days. If tolerated, increase to 400 mg orally daily in divided doses every 6–8 hours. If necessary, dosage may be increased after 3 days to 600 mg orally daily in divided doses every 6–8 hours.</entry>
</row>
<row>
<entry valign="top" align="center"><term class="no-emphasis" id="term-00004">Aminophylline</term><newline/>
(<term class="no-emphasis" id="term-00005">Norphyl, Phyllocontin, Quibron-T</term>)</entry>
<entry valign="top" align="center">Loading dose: 4.6 mg/kg of ideal body weight IV over 30 minutes, then maintenance infusion of 0.4 mg/kg/hour up to a maximum of 900 mg/day unless higher doses are required to reach a target level of 10 mcg/mL.<newline/>
<emphasis effect="italics">Adults over age 60:</emphasis> 0.3 mg/kg/hour IV, up to a maximum of 400 mg/day unless higher doses required to reach a target level of 10 mcg/mL.</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Emphasis Table: Xanthines</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
<section id="sect-00004">
<title>Adverse Effects and Contraindications</title>
<para id="para-00006">Close monitoring and individualized dosing are essential when utilizing xanthines in respiratory therapy. Xanthines can have a variety of potential adverse effects, including nausea, vomiting, restlessness, nervousness, increased heart rate, and tremors. The number of adverse effects is partly why xanthines are not as widely used as they formerly were. Clients with hypersensitivity, seizure disorder, hyperthyroidism, and severe cardiac arrhythmias should not use xanthines (Khan, 2021).</para>
<para id="para-00007"><link target-id="table-00002" document="m00402"/> is a drug prototype table for xanthines featuring theophylline. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00002">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="2*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Xanthine<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Relaxes the smooth muscles located in the bronchial airways and pulmonary blood vessels</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
<emphasis effect="bold"><span class="blue-text">Parenteral theophylline (preferred route) for acute bronchospasm in clients not currently receiving theophylline:</span></emphasis><newline/>
Loading dose: 4.6 mg/kg of ideal body weight IV over 30 minutes, then maintenance infusion of 400–1600 mg/day<newline/>
<emphasis effect="italics">Adults older than age 60:</emphasis> 0.3 mg/kg/hour IV, up to a maximum of 17 mg/hour.<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Oral theophylline for acute bronchospasm in clients not currently receiving theophylline:</span></emphasis><newline/>
<emphasis effect="italics">Adults age 60 and younger:</emphasis> 5 mg/kg orally, then 300 mg (immediate-release solution/elixir) orally daily in divided doses every 6–8 hours for 3 days. If tolerated, increase to 400 mg orally daily in divided doses every 6–8 hours. If necessary, dosage may be increased after 3 days to 600 mg orally daily in divided doses every 6–8 hours.</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
Acute and chronic bronchospasm<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Bronchodilation</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Allopurinol<newline/>
Calcium channel blockers<newline/>
Macrolides<newline/>
Methotrexate<newline/>
Nicotine<newline/>
St. John’s wort<newline/>
Many others (see drug reference for full list)<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
Caffeine<newline/>
Alcohol<newline/>
High-carbohydrate, low-protein diet</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Dizziness<newline/>
Restlessness<newline/>
Headache<newline/>
Palpitations<newline/>
Tachycardia<newline/>
Nausea<newline/>
Vomiting<newline/>
Diarrhea</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity<newline/>
Peptic ulcer<newline/>
Poorly controlled seizure disorder<newline count="2"/>
Caution:<newline/>
Older adults<newline/>
COPD<newline/>
Liver disease<newline/>
Diabetes</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Theophylline</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
</section>
<section id="sect-00005">
<title>Leukotriene Modifiers</title>
<para id="para-00008"><term id="term-00006">Leukotriene modifiers</term>, also known as leukotriene receptor antagonists or leukotriene inhibitors, are a class of medications used to manage various inflammatory conditions, particularly asthma. These medications target <term id="term-00007">leukotrienes</term>, which are inflammatory substances produced in the body in response to certain triggers. By blocking the effects of leukotrienes, leukotriene modifiers help to reduce inflammation, bronchoconstriction, and mucus production in the airways. This can lead to improved asthma control, decreased frequency of asthma symptoms, and reduced need for rescue medications.</para>
<para id="para-00009">Leukotriene modifiers, such as montelukast, zafirlukast, and zileuton, are typically administered orally and are often used as adjunctive therapy in combination with other asthma medications. Montelukast is taken at night due to its short half-life and to ensure peak drug levels with symptom onset (Cleveland Clinic, 2023b).</para>
<para id="para-00010"><link target-id="table-00003" document="m00402"/> lists common leukotriene modifiers and typical routes and dosing for adult clients.</para>
<table class="vertically-tight" id="table-00003">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="2*"/>
<tbody>
<row>
<entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Drug</span></emphasis></entry>
<entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Routes and Dosage Ranges</span></emphasis></entry>
</row>
<row>
<entry valign="top" align="center"><term class="no-emphasis" id="term-00008">Montelukast</term><newline/>
(<term class="no-emphasis" id="term-00009">Singulair</term>)</entry>
<entry valign="top" align="left">1 10-mg tablet orally daily, in the evening.</entry>
</row>
<row>
<entry valign="top" align="center"><term class="no-emphasis" id="term-00010">Zafirlukast</term><newline/>
(<term class="no-emphasis" id="term-00011">Accolate</term>)</entry>
<entry valign="top" align="left">1 20-mg tablet orally twice daily.</entry>
</row>
<row>
<entry valign="top" align="center"><term class="no-emphasis" id="term-00012">Zileuton</term><newline/>
(<term class="no-emphasis" id="term-00013">Zyflo, Zyflo CR</term>)</entry>
<entry valign="top" align="left">2 600-mg tablets orally twice daily within 1 hour after morning and evening meals; total dose: 2400 mg.</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Emphasis Table: Leukotriene Modifiers</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
<section id="sect-00006">
<title>Adverse Effects and Contraindications</title>
<para id="para-00011">Montelukast is typically well tolerated; side effects include fever, headache, cough, abdominal pain, and diarrhea. Clients with hypersensitivity should not take this drug. Zafirlukast can cause headache, nausea, diarrhea, dizziness, and vomiting. Zileuton’s most common adverse effects are sinusitis and nausea. Both zafirlukast and zileuton should be avoided in clients who are hypersensitive and in clients with hepatic impairment.</para>
<para id="para-00012"><link target-id="table-00004" document="m00402"/> is a drug prototype table for leukotriene modifiers featuring montelukast. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00004">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="2*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Leukotriene modifier<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Decreases action of leukotrienes</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
1 10-mg tablet orally daily, in the evening.</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
Asthma<newline/>
Exercise-induced bronchospasm<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Reduced asthmatic symptoms</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Gemfibrozil<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Headaches<newline/>
Dizziness<newline/>
Epistaxis<newline/>
Urticaria</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity<newline count="2"/>
Caution:<newline/>
Montelukast is linked to psychological reactions such as agitation, aggression, depression, and suicidal thinking. It should be used cautiously in clients with mental health disorders and under supervision of the health care provider.</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Montelukast</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
<note class="black-box" id="note-00001">
<para id="para-00013"><emphasis effect="bold">Montelukast</emphasis></para>
<para id="para-00014">Serious neuropsychiatric events have been reported in clients taking montelukast. Agitation, hostile and/or aggressive behavior, depression, and suicidality have been seen.</para>
</note>
</section>
</section>
<section id="sect-00007">
<title>Mast Cell Stabilizers</title>
<para id="para-00015"><term id="term-00014">Mast cell stabilizers</term> are medications used to manage allergic conditions such as asthma and allergic rhinitis. These medications work by preventing the release of inflammatory substances, particularly <term id="term-00015">histamine</term>, from <term id="term-00016">mast cells</term>. Histamine is a key mediator of allergic reactions and is responsible for the symptoms of itching, sneezing, wheezing, and swelling. By stabilizing mast cells, mast cell stabilizers help to inhibit the release of histamine and other inflammatory mediators, thereby reducing the allergic response.</para>
<para id="para-00016">Cromolyn sodium is one of the commonly used mast cell stabilizers. It is available as an inhaler for asthma and is most effective when used prophylactically, before exposure to triggers, because it does not provide immediate relief of symptoms (Science Direct, 2019).</para>
<section id="sect-00008">
<title>Adverse Effects and Contraindications</title>
<para id="para-00017">Mast cell stabilizers are generally well tolerated, with minimal systemic absorption and few side effects. Side effects that may occur include coughing, sneezing, nausea, wheezing, and nasal congestion. Clients with a hypersensitivity to the drug should not take cromolyn (DailyMed, <emphasis effect="italics">Cromolyn sodium</emphasis>, 2022).</para>
<para id="para-00018"><link target-id="table-00005" document="m00402"/> is a drug prototype table for mast cell stabilizers featuring <term class="no-emphasis" id="term-00017">cromolyn sodium</term> (<term class="no-emphasis" id="term-00018">Intal</term>). It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00005">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="2*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Mast cell stabilizer<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Inhibits the release of mediators from mast cells<newline/>
Indirectly blocks calcium ions from entering the mast cell, thereby preventing mediator release</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
1 ampule (20 mg/2 mL) administered by nebulization 4 times a day at regular intervals</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
Asthma symptom prophylaxis<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Reduced incidence of asthmatic symptoms</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
No significant interactions<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Headache<newline/>
Diarrhea<newline/>
Nausea<newline/>
Myalgia<newline/>
Rash<newline/>
Abdominal pain</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Cromolyn Sodium</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)caption</caption>
</table>
</section>
</section>
<section id="sect-00009">
<title>Nursing Implications</title>
<para id="para-00019">The nurse should do the following for clients who are taking xanthines, leukotriene modifiers, and mast cell stabilizers:</para>
<list list-type="bulleted" id="list-00002">
<item>Assess for hypersensitivity.</item>
<item>Ensure the client’s medication list is up to date.</item>
<item>Monitor for signs and symptoms of toxicity including blurred vision, nausea and vomiting, headache, and confusion.</item>
<item>For leukotriene modifiers, assess for neuropsychiatric symptoms including depression, hallucinations, suicidal thoughts, and anxiety.</item>
<item>Provide client teaching regarding the drug and when to call the health care provider. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00002">
<para id="para-00020"><emphasis effect="bold">The client taking a xanthine, leukotriene modifier, or mast cell stabilizer should:</emphasis></para>
<list list-type="bulleted" id="list-00003">
<item>Take the drug as prescribed without skipping doses or stopping therapy, even if asymptomatic.</item>
<item>Report all adverse reactions including headache, diarrhea, nausea, abdominal pain, irritability, and suicidal thoughts.</item>
<item>Report any worsening symptoms including shortness of breath, wheezing, or increase in allergy symptoms such as runny nose and itchy, watery eyes.</item>
<item>Take drug with water and/or food to minimize GI distress.</item>
<item>Keep appointments for lab draws to monitor medication levels.</item>
</list>
<para id="para-00021"><emphasis effect="bold">The client taking a xanthine, leukotriene modifier, or mast cell stabilizer<emphasis effect="italics"> should</emphasis> <emphasis effect="italics">not:</emphasis></emphasis></para>
<list list-type="bulleted" id="list-00004">
<item>Stop taking the drug abruptly.</item>
<item>Use these medications as rescue medications in acute asthma attacks.</item>
</list>
</note>
</section>
</section>
<section id="sect-00010">
<title>Chapter Summary</title>
<para id="para-00022">This chapter provided an overview of various medications commonly used in the management of lower respiratory conditions: adrenergic drugs, anticholinergics, corticosteroids, xanthines, leukotriene modifiers, and mast cell stabilizers.</para>
<para id="para-00023">The chapter provided an understanding of the different classes of respiratory medications and their mechanisms of action. Each medication class has its unique role in managing lower respiratory conditions, and a combination of these medications may be used for optimal control of symptoms, prevention of exacerbations, and improved quality of life for clients with lower respiratory conditions. Health care professionals should carefully consider the client’s individual needs, characteristics, and treatment goals when selecting and prescribing these medications.</para>
</section>
<section class="review-questions" id="sect-00011">
<title>Review Questions</title>
<exercise id="exer-00001"><problem id="prob-00001"><para id="para-00024"><link class="os-embed" url="#exercise/PHAR_Ch25_Sec01_RQ1"/></para></problem></exercise>
<exercise id="exer-00002"><problem id="prob-00002"><para id="para-00025"><link class="os-embed" url="#exercise/PHAR_Ch25_Sec02_RQ2"/></para></problem></exercise>
<exercise id="exer-00003"><problem id="prob-00003"><para id="para-00026"><link class="os-embed" url="#exercise/PHAR_Ch25_Sec03_RQ3"/></para></problem></exercise>
<exercise id="exer-00004"><problem id="prob-00004"><para id="para-00027"><link class="os-embed" url="#exercise/PHAR_Ch25_Sec01_RQ4"/></para></problem></exercise>
<exercise id="exer-00005"><problem id="prob-00005"><para id="para-00028"><link class="os-embed" url="#exercise/PHAR_Ch25_Sec03_RQ5"/></para></problem></exercise>
<exercise id="exer-00006"><problem id="prob-00006"><para id="para-00029"><link class="os-embed" url="#exercise/PHAR_Ch25_Sec03_RQ6"/></para></problem></exercise>
<exercise id="exer-00007"><problem id="prob-00007"><para id="para-00030"><link class="os-embed" url="#exercise/PHAR_Ch25_Sec01_RQ7"/></para></problem></exercise>
<exercise id="exer-00008"><problem id="prob-00008"><para id="para-00031"><link class="os-embed" url="#exercise/PHAR_Ch25_Sec02_RQ8"/></para></problem></exercise>
<exercise id="exer-00009"><problem id="prob-00009"><para id="para-00032"><link class="os-embed" url="#exercise/PHAR_Ch25_Sec01_RQ9"/></para></problem></exercise>
<exercise id="exer-00010"><problem id="prob-00010"><para id="para-00033"><link class="os-embed" url="#exercise/PHAR_Ch25_Sec01_RQ10"/></para></problem></exercise>
</section>
<section class="references" id="sect-00012">
<para id="para-00034">Cleveland Clinic. (2023a). <emphasis effect="italics">Corticosteroids</emphasis>. https://my.clevelandclinic.org/health/drugs/4812-corticosteroids</para>
<para id="para-00035">Cleveland Clinic. (2023b). <emphasis effect="italics">Leukotriene modifiers: Treatment &amp; definition</emphasis>. https://my.clevelandclinic.org/health/drugs/14278-leukotriene-modifiers</para>
<para id="para-00036">Cunha, J. (2021, September 9). <emphasis effect="italics">Theophylline: Generic, uses, side effects, dosages, interactions, warnings</emphasis>. RxList. https://www.rxlist.com/theophylline/generic-drug.htm</para>
<para id="para-00037">DailyMed. (Updated January 1, 2023). <emphasis effect="italics">Albuterol sulfate aerosol, metered</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c64ab5d-f8a2-440a-a929-cb8188d0e8b4</para>
<para id="para-00038">DailyMed. (Updated August 27, 2023). <emphasis effect="italics">Aminophylline, injection, solution.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9a663ef3-881f-48bd-2689-3713b24545c2</para>
<para id="para-00039">DailyMed. (Updated January 19, 2021).<emphasis effect="italics"> Atrovent HFA – ipratropium bromide aerosol, metered.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=170e98ef-5560-4068-be7d-e649068eb884</para>
<para id="para-00040">DailyMed. (Updated September 21, 2018). <emphasis effect="italics">Budesonide capsule</emphasis>. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c2ce3a8-7125-4ee0-afae-73a9cac8fd31</para>
<para id="para-00041">DailyMed. (Updated May 4, 2022). <emphasis effect="italics">Cromolyn sodium – inhalant</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aebec664-ed80-447c-9789-0cf47c8b7429</para>
<para id="para-00042">DailyMed. (Updated March 23, 2022).<emphasis effect="italics"> Ephedrine hydrochloride tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bcb81dc1-d854-30c0-e053-2a95a90a9fc7</para>
<para id="para-00043">DailyMed. (Updated July 10, 2018).<emphasis effect="italics"> Epinephrine – adrenalinum liquid.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89fefa8e-dbad-4150-858e-c14d1f31abbf</para>
<para id="para-00044">DailyMed. (Updated August 18, 2021).<emphasis effect="italics"> Fluticasone propionate spray, metered.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b49ed7c1-123e-4b1d-fea6-0c6839fd9d6a</para>
<para id="para-00045">DailyMed. (Updated October 27, 2022). <emphasis effect="italics">Levalbuterol solution</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f1c4f22-d420-495c-8f64-33532638215f</para>
<para id="para-00046">Daily Med. (Updated February 9, 2023). <emphasis effect="italics">Methylprednisolone.</emphasis> https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e38b09c-da41-4ee3-8f99-812d3276d551</para>
<para id="para-00047">DailyMed. (Updated June 21, 2021). <emphasis effect="italics">Montelukast tablet, film coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97a682c2-7e00-4d07-a5ac-4436c977f842</para>
<para id="para-00048">DailyMed. (Updated January 31, 2018). <emphasis effect="italics">Prednisone tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9d6774e-45f6-419f-b388-8dfb4dd34944</para>
<para id="para-00049">DailyMed. (Updated September 27, 2022). <emphasis effect="italics">QVAR Redihaler – beclomethasone dipropionate HFA aerosol, metered</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cada897a-264e-450d-ae00-36e7fe747080</para>
<para id="para-00050">DailyMed. (Updated September 27, 2012). <emphasis effect="italics">Serevent diskus – salmeterol xinafoate powder, metered.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4925b2c-bde1-45fd-8109-dc75bee3b7a3</para>
<para id="para-00051">DailyMed. (Updated May 23, 2023). <emphasis effect="italics">Spiriva Respimat – tiotropium bromide inhalation spray, metered.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b656b14-fcaa-2741-f6f0-e0be48971c02</para>
<para id="para-00052">DailyMed. (Updated October 28, 2022). <emphasis effect="italics">Theophylline solution</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b685384-5d96-46fa-b93b-e96538a2cfe7</para>
<para id="para-00053">DailyMed. (Updated November 25, 2018). <emphasis effect="italics">Zafirlukast tablet, coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0262e192-94f4-423d-a58e-bb374dc106fe</para>
<para id="para-00054">DailyMed. (Updated August 23, 2022). <emphasis effect="italics">Zileuton tablet, multilayer, extended release.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d3d8cd1-e1a5-4a2e-a09d-9420b0168922<emphasis effect="italics"/></para>
<para id="para-00055">Drugbank Online. (2023). <emphasis effect="italics">Ephedrine</emphasis>. https://go.drugbank.com/drugs/DB01364</para>
<para id="para-00056">Dalal, R., &amp; Grujic, D. (2023). <emphasis effect="italics">Epinephrine.</emphasis> StatPearls.<emphasis effect="italics"/> https://www.ncbi.nlm.nih.gov/books/NBK482160/</para>
<para id="para-00057">Farzam, K., Kidron, A., &amp; Lakhkar, A. D. (2022). <emphasis effect="italics">Adrenergic drugs</emphasis>. StatPearls.<emphasis effect="italics"/> https://www.ncbi.nlm.nih.gov/books/NBK534230/</para>
<para id="para-00058">Hsu, E., &amp; Bajaj, T. (2023, June 20). <emphasis effect="italics">Beta2-Agonists</emphasis>. Stat Pearls. https://www.ncbi.nlm.nih.gov/books/NBK542249/</para>
<para id="para-00059">Khan, S. (2021, October 22). <emphasis effect="italics">Xanthine derivatives: Drug class, uses, side effects, drug names</emphasis>. RxList. https://www.rxlist.com/how_do_xanthine_derivatives_work/drug-class.htm</para>
<para id="para-00060">Martinez-Pitre, J., Sabulla, B. R., &amp; Cascella, M. (2023). <emphasis effect="italics">Restrictive lung disease</emphasis>. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK560880/</para>
<para id="para-00061">Science Direct. (2019). <emphasis effect="italics">Mast cell stabilizer</emphasis>. https://www.sciencedirect.com/topics/nursing-and-health-professions/mast-cell-stabilizer</para>
<para id="para-00062">Widysanto, A., &amp; Mathew, G. (2022). <emphasis effect="italics">Chronic bronchitis</emphasis>. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK482437/</para>
<para id="para-00063">Williams, D. M. (2018). <emphasis effect="italics">Clinical pharmacology of corticosteroids</emphasis>. <emphasis effect="italics">Respiratory Care, 63</emphasis>(6), 655–670. https://rc.rcjournal.com/content/63/6/655</para>
</section>
</content>
<glossary>
<definition id="def-00001"><term>histamine</term> <meaning>a chemical in the body that causes many symptoms of allergies such as runny nose or sneezing</meaning></definition>
<definition id="def-00002"><term>leukotrienes</term> <meaning>a group of inflammatory mediators that are primarily responsible for bronchoconstriction</meaning></definition>
<definition id="def-00003"><term>leukotriene modifiers</term> <meaning>medications that inhibit leukotriene-related enzymes and oppose inflammatory mediators.</meaning></definition>
<definition id="def-00004"><term>mast cells</term> <meaning>cells that play a role in the immune system and help control immune responses; contain chemicals such as histamine</meaning></definition>
<definition id="def-00005"><term>mast cell stabilizers</term> <meaning>prevent mast cell degranulation and mediator release</meaning></definition>
<definition id="def-00006"><term>xanthines</term> <meaning>class of compounds derived from purine that have stimulant properties and can relax airway smooth muscle</meaning></definition>
</glossary>
</document>